Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]
" Ashley Attilio 3 months ago " Top-tier professionalism
doi: 10.1186/s13059-014-0550-8
Physiol Genomics 38:386401 Iqbal MJ, Kabeer A, Abbas Z, Siddiqui HA, Calina D, Sharifi-Rad J et al (2024) Interplay of oxidative stress, cellular communication and signaling pathways in cancer
Many commercial formulations contain higher concentrations
Beyond thiamine, other B vitamins also demonstrate significant immunomodulatory properties in the context of liver disease
